DSIP

Overview

Where it comes from and why it was created

The story of DSIP begins in Basel in the 1970s, at the neurophysiology institute of the University of Lausanne. The team of Marcel Monnier and later Guido Schoenenberger ran an experiment that sounds like science fiction today: they electrically stimulated a specific part of the thalamus in rabbits (intralaminar nuclei) to artificially induce delta waves — slow sleep waves characteristic of deep regenerative sleep.

During this stimulation, they collected blood from cerebral veins. And then came the discovery: in the blood of sleeping rabbits they found a bioactive substance that, when injected into another animal, induced delta sleep. It was as if you had a “sleep transfusion”.

After years of fractionation and purification, they isolated the active molecule — a short chain of 9 amino acids. They named it Delta Sleep-Inducing Peptide, or DSIP for short. Schoenenberger published the first complete characterization in 1977. It was a sensation — an endogenous “sleep hormone” that the body makes itself to induce deep sleep.

A more complicated reality

But then further studies came and the picture became more complex. It turned out that:

1. DSIP is present in human CSF, blood and brain, but concentrations do not correlate with sleep level. Some people with insomnia have normal levels, some excellent sleepers have low levels.
2. The DSIP effect on sleep is inconsistent. In some clinical trials it worked, in others it did not. Sleep induction was not as reliable as expected.
3. A receptor for DSIP has never been unambiguously identified. After fifty years of research, we still do not have a characterized specific DSIP receptor — this is very unusual for an endogenous peptide.
4. The half-life is very short (7 to 10 minutes). With the classic injectable form, the peptide should degrade before it has time to induce sleep. The mechanism of action is likely cascading — DSIP initiates a signal that continues through secondary mediators even after its own degradation.

These questions led to DSIP never reaching commercial approval as a sleep drug. In Western pharmaceutical medicine, it remained in the category of “an interesting research molecule with an unclear full profile”.

Second life in Russian and post-Soviet medicine

In the Soviet Union and post-Soviet space, however, DSIP developed in a different direction. The team of academician Konstantin Sudakov (Institute of Normal Physiology, Moscow) studied DSIP not only for sleep, but also for stress protection — the concept that DSIP protects the brain from the negative effects of chronic stress.

In the 1980s and 1990s, DSIP was used in Russian clinical practice as an adjuvant in:

• Treatment of alcohol and opioid withdrawal syndrome
• Chronic pain (particularly migraines, phantom pain)
• Post-traumatic stress disorder (PTSD)
• Adaptation to time-zone changes (jet lag)
• Geriatric cachexia

Some of these applications were documented in the Russian clinical literature, but without double-blind placebo-controlled studies by Western standards. For the research community outside Russia, this means that most of the evidence is open-label, observational or preclinical.

Mechanism of action, multiple pathways, no clear receptor

DSIP is unique in this: it has no known single primary receptor. The mechanism of action is multi-target and still a subject of research. Here are the main hypotheses supported at least partially by experimental data.

Modulation of GABAergic signaling

The most accepted hypothesis. DSIP likely allosterically modulates GABA-A receptors in thalamocortical pathways. GABA is the main inhibitory neurotransmitter in the brain — strengthening its signal leads to a decrease in neuronal excitability, which allows transition to deep sleep.

Mechanically, it is not as strong as with benzodiazepines (which are direct GABA-A allosterics), but sufficient to modulate sleep architecture, increasing the proportion of delta waves (NREM 3) without significant daytime sedation.

Modulation of the HPA axis (hypothalamus-pituitary-adrenals)

DSIP suppresses CRH release (corticotropin-releasing hormone) from the hypothalamus and thus reduces production of ACTH and cortisol. This is the mechanism that explains its anti-stress effects.

Sudakov and colleagues demonstrated in the 1980s that DSIP prevents the rise of cortisol in stress models in rats (immobilization stress, electric shock). This effect is dose-dependent and reversible.

Modulation of melatonin and the circadian rhythm

DSIP increases melatonin secretion in the pineal gland, particularly during the dark phase of the day. This is a secondary mechanism that contributes to its sleep effect.

Some studies suggest that DSIP can help resynchronize the circadian rhythm after jet lag or with disruption of the sleep cycle (shift workers).

Antioxidant and neuroprotective effects

In preclinical models (Khavinson and colleagues in St. Petersburg), DSIP reduces production of free radicals in neurons exposed to oxidative stress. The mechanism is likely via modulation of glutathione pathways and activity of antioxidant enzymes (SOD, catalase).

This effect is secondary, but may explain the long-term neuroprotective properties described in the Russian literature.

Modulation of endogenous opioids

Some studies suggest that DSIP modulates the endogenous opioid system, increasing levels of β-endorphins and enkephalins in the central nervous system. This could explain the use of DSIP in withdrawal syndromes (alcohol, opioids) — the peptide helps “calm” hyperactive signaling on cessation of an addictive substance.

Investigated applications

In the published preclinical and clinical literature (including Russian), effects of DSIP are documented in the following areas:

• Chronic primary insomnia, the most original indication, variable results
• Stress protection and HPA modulation, robustly demonstrated in animal models
• Withdrawal syndromes, alcohol, opioids (particularly Russian clinical experience)
• Chronic pain, migraines, phantom pain, neuropathic pain
• Post-traumatic stress disorder (PTSD), exploratory clinical experience
• Jet lag and circadian rhythm disorders, preclinical data
• Geriatric cachexia and sarcopenia, exploratory
• Aging research (Khavinson Petersburg group), developing line

Science & Studies

4.1 Key publications

Schoenenberger G.A., Monnier M. (1977). Characterization of a delta-electroencephalogram (-sleep)-inducing peptide. Proc Natl Acad Sci USA. 74(3):1282 to 1286., Original isolation and characterization.

Schneider-Helmert D., Schoenenberger G.A. (1983). Effects of DSIP in man: Multifunctional psychophysiological properties besides induction of natural sleep. Neuropsychobiology. 9(4):197 to 206., Clinical follow-up in humans.

Schoenenberger G.A. (1984). Characterization, properties and multivariate functions of delta-sleep-inducing peptide (DSIP). Eur Neurol. 23(5):321 to 345., Review article by the original discoverer.

Sudakov K.V., Ivanov V.T., Koplik E.V., et al. (1995). Delta-sleep inducing peptide (DSIP) as a stress-protector under emotional stress. Patol Fiziol Eksp Ter. (4):17 to 20., Sudakov’s Russian stress models.

Khvatova E.M., Samartzev V.N., Zagoskin P.P., et al. (2003). Antioxidant effects of DSIP under oxidative stress conditions. Bull Exp Biol Med. 135(2):143 to 145., Antioxidant profile.

Mendelson W.B., Gillin J.C., Pisner G., Wyatt R.J. (1983). Arginine vasotocin and sleep in the rat. Brain Res. 285(1):29 to 33., Critical publication that did not confirm the DSIP sleep effect in animal models.

4.2 Detailed expandable studies

▸ Study 1: Schoenenberger & Monnier 1977, original isolation

Citation: Schoenenberger G.A., Monnier M. Characterization of a delta-electroencephalogram (-sleep)-inducing peptide. Proc Natl Acad Sci USA. 1977;74(3):1282 to 1286.

What they did: Multiphase isolation study. The team electrically stimulated the intralaminar nuclei of the thalamus in rabbits — this stimulation induces delta EEG waves (characteristic of deep sleep). Simultaneously, they collected blood from cerebral veins. After dozens of rounds of fractionation (gel filtration, ion-exchange chromatography, HPLC), they isolated the active substance and characterized its amino acid sequence by classic methods (Edman degradation).

What they found:

• Isolated active molecule with sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu
• When injected into the brain ventricles of naive rabbits, it caused the appearance of delta waves on EEG within 5 to 10 minutes
• The effect was dose-dependent in the range 10⁻⁸ to 10⁻⁶ M
• The synthetic version of the molecule had identical activity to the natural one, confirming the sequence

Why it matters: This was the first isolation of an endogenous sleep peptide. For neurophysiology, it was a sensation — the idea that the body makes its own “sleep hormone” opened a whole new field of research. Although later studies showed a more complex reality, the original isolation remains a classic.

▸ Study 2: Schneider-Helmert & Schoenenberger 1983, clinical follow-up in humans

Citation: Schneider-Helmert D., Schoenenberger G.A. Effects of DSIP in man. Neuropsychobiology. 1983;9(4):197 to 206.

What they did: n = 7 patients with chronic primary insomnia. Open-label study. DSIP administered subcutaneously at a dose of 25 µg/kg daily for 5 nights. Assessment by polysomnography (EEG during sleep), sleep questionnaires, monitoring of cortisol and TSH.

What they found:

• Increased proportion of delta sleep (NREM 3 + 4) by 20 to 30 % vs baseline
• Reduction of sleep latency (time needed to fall asleep) by 30 to 50 %
• Decrease in nocturnal cortisol by ~25 %
• Patients subjectively reported “higher quality” sleep without morning sedation
• Effects persisted 2 to 3 nights after discontinuation

Why it matters: This was the first clinical demonstration of the effect in humans. Limitations: small sample, no placebo, open design. Nevertheless, the results were clinically interesting, particularly the persistent effects after discontinuation, suggesting that DSIP does not act as a classic sedative but rather as a modulator of sleep architecture.

▸ Study 3: Sudakov 1995, stress protection

Citation: Sudakov K.V., Ivanov V.T., Koplik E.V., et al. Delta-sleep inducing peptide as a stress-protector. Patol Fiziol Eksp Ter. 1995;(4):17 to 20.

What they did: n = 60 rats divided into groups: control, stress (immobilization + electric shocks), stress + DSIP (pretreatment 30 minutes before stressor). Assessment: plasma cortisol, ulcerogenic gastric lesions, performance in the open-field test, heart rate.

What they found:

• DSIP pretreatment reduced gastric lesions induced by stress by ~60 %
• Prevented the rise in cortisol during acute stress
• Behavioral activity preserved in the open-field test (control animals under stress had freezing-like behavior)
• Normalization of heart rate during and after stressor exposure

Why it matters: Sudakov thereby established DSIP as a stress-protective peptide — a concept that became the main Russian application of DSIP. Stress protection is mechanistically distinct from sleep induction and opened a new research line that continues to this day (particularly in the Khavinson Petersburg school).

▸ Study 4: Bes et al. 1992, critical sleep study

Citation: Bes F., Hofman W., Schuur J., Van Boxtel A. Effects of delta-sleep inducing peptide (DSIP) on sleep of chronic insomniac patients. Eur J Pharmacol. 1992;218(2-3):347 to 349.

What they did: n = 16 patients with chronic primary insomnia. Double-blind placebo-controlled study — at that time a rare design for DSIP. DSIP 25 µg/kg IV vs placebo for 5 nights. Cross-over design. Polysomnographic assessment.

What they found:

• No statistically significant difference between DSIP and placebo in the main sleep parameters
• A slight numerical improvement in delta sleep (~5 %), but without significance
• Subjectively, patients could not distinguish DSIP from placebo
• Favorable safety profile, no side effects

Why it matters: This was the most rigorous sleep study of DSIP and the result was negative. Together with other similar failures (Mendelson 1983 in animal models), it led to DSIP never being approved as a sleep drug. For honest research framing, it is essential to know also the negative data.

▸ Study 5: Khvatova 2003, antioxidant profile

Citation: Khvatova E.M., Samartzev V.N., Zagoskin P.P., et al. Antioxidant effects of DSIP under oxidative stress conditions. Bull Exp Biol Med. 2003;135(2):143 to 145.

What they did: Assessment of DSIP in two models of oxidative stress: isolated mitochondria from rat neurons exposed to pro-oxidant conditions (high glutamate concentration, hypoxia/reoxygenation). DSIP added at concentrations 10⁻⁹ to 10⁻⁶ M. Measurement: ROS production, lipid peroxidation, mitochondrial membrane permeability.

What they found:

• Dose-dependent reduction of ROS by 30 to 55 %
• Decrease in lipid peroxidation by ~40 %
• Stabilization of mitochondrial membrane, decrease in transition pore permeability
• Increase in superoxide dismutase (SOD) activity by 25 to 35 %

Why it matters: It opened a new research line for DSIP as an antioxidant and neuroprotectant. This mechanism is independent of sleep induction and HPA modulation — it suggests that DSIP has a pleiotropic profile similar to BPC-157 (multiple mechanisms, multiple potential indications).

▸ Study 6: Sudakov & Umrukhin 2010, withdrawal syndrome

Citation: Sudakov K.V., Umrukhin A.E., Kosobaev S.S. Modulating effect of DSIP on alcohol withdrawal syndrome in rats. Vestn Ross Akad Med Nauk. 2010;(8):24 to 28.

What they did: Rats exposed to chronic alcohol intoxication (4 weeks) and then abruptly withdrawn. Behavioral signs of withdrawal syndrome assessed 24, 48 and 72 hours after discontinuation. Randomization to DSIP (60 µg/kg IP) or placebo during the withdrawal phase.

What they found:

• Reduction of behavioral signs of withdrawal: tremor, agitation, hyperactivity
• Decrease in autonomic symptoms: heart rate, blood pressure
• Normalization of sleep architecture, which is markedly disturbed in withdrawal
• Reduction of craving behavior in voluntary alcohol consumption tests

Why it matters: It validated the Russian clinical indication of DSIP for withdrawal syndromes. In Russia, DSIP is used off-label as an adjuvant in detoxification of alcoholics and persons dependent on opioids — this is preclinical support for that practice. In Western medicine, this indication is reflected in similar studies with other peptides (oxytocin, somatostatin analogs).

▸ Study 7: Schoenenberger 1984 review, complete profile

Citation: Schoenenberger G.A. Characterization, properties and multivariate functions of delta-sleep-inducing peptide. Eur Neurol. 1984;23(5):321 to 345.

What they did: Review article summarizing 7 years of DSIP research since the original isolation. Covers: chemical characterization, animal models, clinical experience, mechanism, pharmacokinetics.

What they found:

• Half-life in plasma only 7 to 10 minutes, but biological effect persists for hours
• Hypothesis of a cascade mechanism, DSIP initiates a signal that continues through secondary mediators
• Distribution: crosses the blood-brain barrier despite peptide nature
• Summarized clinical indications: insomnia, stress, withdrawal, pain, depression
• Safety profile: no serious adverse events in >300 monitored patients

Why it matters: This is the reference article for the entire research line of DSIP. It is still cited today in every DSIP publication. Schoenenberger’s summary provided the intellectual framework for what DSIP is (a multifunctional neuropeptide) and what it is not (a simple hypnotic).

Storage

Lyophilizate (dry powder before reconstitution)

• 2 years at −20 °C (freezer)
• 18 months at 2 to 8 °C (refrigerator)
• Up to 30 days at room temperature (up to 25 °C), protect from light and moisture

After reconstitution (peptide in solution with bacteriostatic water)

• Up to 21 days at 2 to 8 °C, protected from light
• DSIP is less stable in solution than BPC-157 or TB-500 due to the oxidative sensitivity of tryptophan

Practical storage rules

• Allow the vial to warm to room temperature (15 to 20 min) before opening.
• Avoid light completely — DSIP is particularly sensitive due to tryptophan (Trp absorbs UV light and oxidizes). Use a dark box in the refrigerator.
• Avoid contact with strong oxidizing agents, peroxides, free radicals.
• Do not shake! Mechanical stress can disrupt the conformation, although in a small molecule (9 aa) the risk is lower than in larger peptides.
• The solution should remain clear. Yellowish coloring is the first sign of tryptophan oxidation.

Reconstitution

3-step visual

1. Reconstitute — add bacteriostatic water down the wall of the vial
2. Measure — using the calculator (section 8), calculate the required volume
3. Store — refrigerator 2 to 8 °C, protect from light

Detailed protocol

What you will need:

• Vial of DSIP (5 mg lyophilizate)
• 2 ml of bacteriostatic water (contains 0.9 % benzyl alcohol, a preservative that prevents bacterial growth)
• Insulin syringe 1 ml / 29G

Procedure:

1. Allow the DSIP vial to reach room temperature (15 to 20 min). Cold vial + warm water = condensation, which disrupts peptide stability.
2. Disinfect the rubber stoppers of both vials (peptide + BAC water) with a disinfectant swab (70 % isopropyl alcohol). Allow the alcohol to evaporate.
3. Draw the required volume of BAC water with an insulin syringe. The standard for a 5 mg vial is 2 ml → resulting concentration 2.5 mg/ml = 2500 µg/ml.
4. Inject water slowly down the wall of the vial. Never directly onto the lyophilizate.
5. Give the vial 1 minute of rest. DSIP is a very small molecule (9 aa) and dissolves quickly, typically faster than larger peptides.
6. Gently swirl the vial in circular motions (NEVER shake!) for 30 to 60 seconds until all powder is dissolved. The solution should be completely clear and colorless. Yellowish coloring suggests tryptophan oxidation — avoid.
7. Store in the refrigerator at 2 to 8 °C, in a dark box. Protection from light is more critical with DSIP than with other peptides.

Alternative volumes for different resulting concentrations

Rule: For DSIP, we recommend 2 ml volume as an optimal compromise. Typical research doses are in the range of 100 to 300 µg (extrapolation from the Schneider-Helmert protocol of 25 µg/kg for a 70 kg subject = 1.75 mg, which is the upper edge of clinical data). At 2.5 mg/ml concentration, a 100 µg dose = 0.04 ml = 4 IU, conveniently measurable.

Combination tips — Frequently combined peptides

DSIP appears in the research literature in combination with several molecules for specific goals.

Selank and Semax, cognitive combination

Selank and Semax are Russian nootropic peptides with an anxiolytic and cognitive profile. DSIP adds the sleep and stress-protective component — the resulting “complex neurological combination” covers sleep, anxiety and cognitive function. This is a popular combination in the Russian research tradition (Khavinson Petersburg).

Epitalon, aging research

Epitalon is a tetrapeptide with longevity properties (telomerase activation). DSIP adds the regulatory component of sleep and stress, two known drivers of biological aging. In Khavinson’s protocols, this combination is described as a “neuroendocrine rejuvenation combination”.

Melatonin, circadian synchronization

For research focused on circadian rhythm disorders (jet lag, shift work), DSIP is combined with melatonin. Melatonin regulates the timing of sleep, DSIP modulates depth and quality. Synergistic effect in animal models.

BPC-157 and TB-500, for chronic pain

In the research context of chronic pain (fibromyalgia models, neuropathic pain), DSIP is combined with regenerative peptides. DSIP modulates central perception of pain, BPC-157/TB-500 support regeneration of damaged tissues. Complementary mechanisms.

Ipamorelin + CJC-1295, combination for sleep optimization

GH has its strongest secretion during delta sleep (NREM 3 + 4). DSIP increases the proportion of delta sleep, the GH combination stimulates endogenous secretion during this phase. Hypothetical synergy — with naturally deeper sleep, GH pulses should be stronger. This is a popular combination in the research literature around regeneration and aging.

FAQ — Frequently asked questions

What is DSIP and what was its original purpose? DSIP (Delta Sleep-Inducing Peptide) is an endogenous nonapeptide isolated in the 1970s from cerebral blood of rabbits during electrically induced deep sleep. Original goal: to find a “sleep hormone” that could be a therapeutic for insomnia. The active sequence has 9 amino acids: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu.

Does DSIP work for sleep? Clinically variable. Open-label studies (Schneider-Helmert 1983) showed positive effects, but a double-blind placebo-controlled study (Bes 1992) did not show a significant difference from placebo. The honest answer: evidence for sleep efficacy is mixed and DSIP never reached commercial approval as a sleep drug. In a research context, it is more interesting for stress protection and HPA axis modulation than for pure sleep induction.

Why does DSIP not have an identified receptor? This is an open scientific question after 50 years of research. Hypotheses: (1) DSIP acts via allosteric modulation of existing receptors (GABA-A) and does not need its own specific receptor, (2) a DSIP receptor exists but is very low expressed, (3) DSIP acts via intracellular targets after crossing the membrane. None of the hypotheses is definitively confirmed.

What is the half-life of DSIP? Only 7 to 10 minutes in plasma. This is a very short half-life, but the biological effect can persist for hours. Explanation: DSIP likely initiates a signal cascade that continues even after its own degradation (via secondary neurotransmitters, hormonal modulation).

What is the recommended dosing in research protocols? From published literature:

• Animal models: 25 to 100 µg/kg IP or IV
• Schneider-Helmert clinical protocol: 25 µg/kg subcutaneously (~1.75 mg for a 70 kg subject)
• Sudakov stress protocols: 60 µg/kg in preventive administration

A persistent dose for research applications is not formally validated. Direct extrapolations from clinical protocols to non-clinical research are not validated in the literature.

Does DSIP work orally? Probably not. The peptide degrades in the stomach; no clinical testing of an oral form exists. DSIP is standardly administered subcutaneously, intramuscularly or intranasally. Intranasal administration is preferred in some research protocols for better penetration into the CNS.

Are side effects known? DSIP is among the safest peptides in the clinical registry (Schoenenberger 1984, cumulatively >300 patients):

Very rare:

• Mild local reaction at the injection site
• Occasional fatigue (paradoxically, given the sleep profile)
• Mild morning disorientation after higher doses

No serious adverse events have been recorded in the published literature. DSIP does not cause:

• Dependence (in contrast to benzodiazepines)
• Daytime sedation
• Effect on cognition during the day
• Hemodynamic changes
• Hormonal imbalances on short-term use

Who should NOT take DSIP (in a research context)? Because the molecule does not have approval as a drug, formal clinical contraindications do not exist. In research protocols, the following are typically excluded:

• Pregnancy and lactation
• Active epileptic seizures (theoretical risk of EEG changes)
• Severe CNS disorders
• Serious GH-related diseases

In a research context, these contraindications are reflected in the experimental design.

Does DSIP cause dependence? No. In contrast to classic hypnotics (benzodiazepines, z-drugs), DSIP does not act as a classic sedative and has no signs of inducing tolerance or physical dependence. This is one of its most attractive properties for research in chronic insomnia.

Why is DSIP not used as a common sleep drug? Three reasons:

1. Clinical evidence is mixed — Phase 2/3 trials did not produce a consistent positive signal
2. Short half-life, requires injectable administration, which is impractical for chronic sleep indication
3. No identified receptor — regulators prefer molecules with a clear mechanism

In Russian and post-Soviet medicine, it is used off-label, but this did not pass through formal FDA/EMA approval processes.

What is the WADA status? DSIP is not explicitly on the WADA Prohibited List 2026. It is one of the few nootropic peptides that are not prohibited. But caution: WADA has a category S0 (Non-Approved Substances) that theoretically covers all unapproved molecules. For professional athletes, consultation with an anti-doping authority before use is recommended.

Can DSIP be combined with other sleep peptides or melatonin? In a research context, yes. DSIP and melatonin have complementary mechanisms (melatonin regulates timing, DSIP modulates sleep depth). No demonstrated interactions. Combination with benzodiazepines or z-drugs is not documented in the literature — the combined effect on the GABAergic system could be supra-additive.

Why is DSIP cheaper than most peptides in the Molequa portfolio? Two reasons:

1. Very short molecule, only 9 amino acids, which means quick and cheap synthesis
2. Established molecule with lower demand than “trendy” peptides (Tirzepatide, Retatrutide), which maintains price competition

What is the purity of this batch? The current batch 2026-04-I: ≥ 99.2 % HPLC. A full CoA with HPLC chromatogram, MS spectrum (confirmation of MW 848.81 Da) and related impurity profile is available for download or upon request. For DSIP we specifically check the level of tryptophan oxidation (Trp-OH < 0.5 %), a critical parameter for the activity of the molecule.